Fluidigm is acquiring DVS in a $208M single-cell technology buyout

Fluidigm ($FLDM) and DVS Sciences announced Wednesday they're merging in a tie-up for which Fluidigm will pay $207.5 million in stock and cash to buy out its San Francisco Bay-area neighbor.

DVS Sciences makes CyTOF, a high-throughput mass cytometer for quantitative individual cell analysis, designed to identify up to 100 biomarkers. It's headquartered in Sunnyvale, CA, with an R&D and instrument-making facility near Toronto, and a sales and support office in the U.K.

San Francisco-based Fluidigm makes genetics instruments, focusing on microfluidic systems. Its instruments and consumables--including chips and reagents--are used primarily by biopharma companies, academic institutions and agricultural biotech. Fluidigm went public in 2011, raising $75 million.

After a close scheduled for February 2014, DVS is set to become a wholly owned subsidiary of Fluidigm.

CEO Gajus Worthington--Courtesy Fluidigm
CEO Gajus Worthington--Courtesy of Fluidigm

"We have long been interested in companies whose technologies are directly in-line with our strategy, have strong top-line growth, and whose management teams fit Fluidigm culturally and would be committed to the success of the combined enterprise," Fluidigm CEO Gajus Worthington said in a statement. "DVS's mass cytometry technology combines the advantages of high-throughput flow cytometry with the accuracy and resolution of mass spectrometry, enabling high-parameter single-cell protein analysis. We believe the acquisition of DVS will increase Fluidigm's single-cell revenue immediately, as well as increase our addressable market to include the approximately $300 million high-end research flow cytometry segment. It also expands our analytical breadth to include single-cell protein analysis."

- read the Fluidigm-DVS press release

Suggested Articles

J.D. Power aims to set the benchmarks in telehealth satisfaction with a new study due this November.

Atomwise plans to screen up to 10 billion virtual compounds for therapies against childhood cancer in collaboration with chemical supplier Enamine.

The Chan Zuckerberg Initiative set aside $68 million for over three dozen projects in an effort to map out every type of cell in the body.